| 摘要 |
The present invention discloses a role for s-nitrosoglutathione in the loss of epithelial barrer integrity. The present invention is further directed to examining the therapeutic value s-nitrosoglutathione and/or a chemical entity that modifies cysteine thiol groups in regulation of intestinal mucosal integrity, function, inflammation, and pain by establishing animal models. This use of s-nitrosoglutathione and/or a chemical entity that modifies cysteine thiol groups provides a novel strategy for therapeutic intervention of pathologies associated with inflammatory barrier disorder such as inflammatory bowel disease, functional bowel disease, and infectious diarrheal disease.
|
